- Home
- JFU vs TENX Comparison
JFU vs TENX Comparison
Compare JFU & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFU | TENX |
|---|---|---|
| Founded | 2006 | 1967 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2M | 56.2M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | JFU | TENX |
|---|---|---|
| Price | $7.37 | $10.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 11.7K | ★ 153.4K |
| Earning Date | 12-09-2022 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3110.57 | N/A |
| EPS | ★ 3.04 | N/A |
| Revenue | ★ $44,573,690.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.78 | ★ N/A |
| Revenue Growth | ★ 8.19 | N/A |
| 52 Week Low | $1.01 | $4.63 |
| 52 Week High | $9.48 | $10.65 |
Technical Indicators
Market Signals| Indicator | JFU | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 70.30 | 73.08 |
| Support Level | $4.57 | $9.40 |
| Resistance Level | $4.94 | $10.55 |
| Average True Range (ATR) | 0.70 | 0.60 |
| MACD | 0.34 | 0.09 |
| Stochastic Oscillator | 60.04 | 88.74 |
Price Performance
Historical ComparisonAbout JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.